Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSigyn Therapeutics Inc

Sigyn Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.028 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
2000
Market Cap
0.19M

Momentum Score

…

Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.03
High
52 Week Price Range
0.01
Low
3.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.54M
Debt / Equity
-
ROE
-2563.58%
Net Debt
2.05M
ROCE
57.24%
Diluted EPS TTM
-1.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.34M -4.15M -2.93M -3.00M -1.26M
Net income -3.34M -4.15M -2.93M -3.00M -1.26M
Selling general administrative 1.75M 1.66M 1.49M 1.27M 0.89M
Gross profit 0.00M 0.00M 0.00M 0.00M 0.00M
Reconciled depreciation 0.01M 0.01M 0.01M 0.02M 0.01M
Ebit - - - -2.54M -0.92M
Ebitda - - -2.27M -2.53M -0.91M
Operating income -2.52M -2.46M -2.15M -2.01M -0.92M
Interest expense 0.86M 2.04M 0.65M 0.46M 0.34M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.86M -2.04M -0.78M -0.46M -0.34M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 2.52M 2.46M 2.15M 2.01M 0.92M
Cost of revenue - - - - 0.00M
Total other income expense net 0.04M 0.35M - -0.54M -
Net income from continuing ops -3.34M -4.15M -2.93M -3.00M -1.26M
Net income applicable to common shares - - - -3.00M -1.26M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.21M 0.32M 0.33M 0.71M 0.69M
Intangible assets - - 0.00M 0.01M 0.02M
Other current assets 0.01M 0.06M 0.01M 0.00M -
Total liab 4.67M 3.73M 2.24M 0.97M 0.59M
Total stockholder equity -4.46M -3.41M -1.90M -0.26M 0.10M
Other current liab 0.00M 0.00M 0.00M 0.00M 0.00M
Common stock - - - 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -14.68M -11.34M -7.20M -4.27M -1.26M
Other assets - - - 0.02M -
Cash 0.01M 0.01M 0.01M 0.34M 0.08M
Total current liabilities 4.61M 3.61M 2.05M 0.73M 0.59M
Net debt 2.05M 2.20M 1.63M 0.31M 0.43M
Short long term debt 2.07M 2.21M 1.64M 0.65M 0.52M
Property plant equipment - - - 0.29M 0.00M
Total current assets 0.02M 0.12M 0.07M 0.39M 0.67M
Net tangible assets - - - -0.27M 0.08M
Net receivables - - - 0.00M -
Inventory 0.00M 0.05M 0.05M 0.05M 0.59M
Accounts payable 0.61M 0.46M 0.33M 0.04M 0.02M
Non currrent assets other 0.07M 0.02M 0.02M 0.02M -
Non current assets total 0.19M 0.20M 0.26M 0.32M 0.02M
Capital lease obligations 0.13M 0.19M 0.24M 0.29M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - 0.00M -0.00M -0.03M -0.01M
Change to liabilities - - - 0.02M 0.02M
Total cashflows from investing activities - - - -0.03M -0.01M
Net borrowings 0.95M 1.31M - 0.20M 0.93M
Total cash from financing activities 0.87M 1.39M 1.50M 2.06M 0.93M
Change to operating activities - - - -0.06M 0.06M
Net income -3.34M -4.15M -2.93M -3.00M -1.26M
Change in cash 0.00M 0.00M -0.33M 0.26M 0.08M
Begin period cash flow 0.01M 0.01M 0.34M 0.08M 0.00M
End period cash flow 0.01M 0.01M 0.01M 0.34M 0.08M
Total cash from operating activities -0.87M -1.38M -1.83M -1.77M -0.83M
Issuance of capital stock - - 0.00M 1.86M -
Depreciation 0.01M 0.01M 0.01M 0.02M 0.01M
Change to netincome - - - 0.82M 0.82M
Capital expenditures 0.00M 0.00M 0.00M 0.03M 0.03M
Change in working capital 1.26M 0.85M 0.31M -0.03M 0.08M
Stock based compensation 0.15M 0.22M - - -
Other non cash items 1.09M 2.04M 0.78M 0.71M 0.34M
Free cash flow -0.87M -1.38M -1.83M -1.80M -0.84M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SIGY
Sigyn Therapeutics Inc		 -
-%		 0.03 - - 114.05 39.04 7082.99 -2.10
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Sigyn Therapeutics Inc

Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

2468 Historic Decatur Road, San Diego, CA, United States, 92106

619 353 0800

https://www.sigyntherapeutics.com

4

Name Title Year Born
Mr. James A. Joyce Ph.D. Co-founder, Chairman & CEO 1962
Mr. Craig P. Roberts Co-founder, CTO & Director 1954
Mr. Jeremy Ferrell CPA, M.B.A. Chief Financial Officer 1970
Ms. Charlene R. Owen Director of Operations NA
Mr. Eric Lynam MS Head of Clinical Affairs NA
Mr. James A. Joyce Ph.D. Co-Founder, Chairman, CEO, Inventor & Interim CFO 1962
Mr. Craig P. Roberts Co-Founder, CTO & Director 1954

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…